UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
SEC File
Number: 0-51891
CUSIP Number: 460378 201
NOTIFICATION OF LATE FILING
|
|
|
(Check One):
|
|
☒ Form 10-K ☐ Form 20-F ☐ Form
11-K ☐ Form 10-Q
☐ Form 10-D ☐ Form
N-SAR ☐ Form N-CSR
|
|
|
|
|
For Period Ended: December 31, 2018
|
|
|
|
|
☐ Transition Report on Form 10-K
|
|
|
|
|
☐ Transition Report on Form 20-F
|
|
|
|
|
☐ Transition Report on Form 11-K
|
|
|
|
|
☐ Transition Report on Form 10-Q
|
|
|
|
|
☐ Transition Report on Form N-SAR
|
|
|
|
|
For the Transition Period Ended:
|
|
|
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the
notification relates:
N/A
PART I REGISTRANT INFORMATION
International Stem Cell Corporation
Full Name of Registrant
N/A
Former Name if
Applicable
5950 Priestly Drive
Address of Principal Executive Office (Street and Number)
Carlsbad, California 92008
City, State and Zip Code
PART II RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b),
the following should be completed. (Check box if appropriate.)
|
|
|
|
|
☒
|
|
(a)
|
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
(b)
|
|
The subject annual report, semi-annual report, transition report on Form
10-K,
Form
20-F,
Form
11-K,
Form
N-SAR
or Form
N-CSR,
or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form
10-Q
or subject distribution report on Form
10-D,
or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
|
The accountants statement or other exhibit required by Rule
12b-25(c)
has been attached if applicable.
|
PART III NARRATIVE
State below in
reasonable detail the reasons why Forms
10-K,
20-F,
11-K,
10-Q,
10-D,
N-SAR,
N-CSR,
or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach
extra sheets if needed.)
International Stem Cell Corporation (the Company) has determined it will not be able to file its
Annual Report on Form
10-K
for the fiscal year ended December 31, 2018 (the Form
10-K)
within the prescribed time period without unreasonable effort or
expense. The Company expects that the Form
10-K
will be filed no later than the fifteenth calendar day following the prescribed due date.
The Form
10-K
cannot be filed by the prescribed due date because the Registrant is experiencing delays
in the compilation of certain financial and other information required to be included in the Form
10-K,
particularly with respect to the completion of various assessments and related disclosures.
PART IV OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
|
|
Sophia Garnette
|
|
|
|
(760)
940-6383
|
(Name)
|
|
|
|
(Area Code) (Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934
or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s). ☒ Yes ☐ No
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the
last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
International Stem Cell Corporation
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: April 1, 2019
|
|
|
|
|
|
|
|
|
INTERNATIONAL STEM CELL CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Sophia Garnette
|
|
|
|
|
|
|
Sophia Garnette
|
|
|
|
|
|
|
Vice President, Legal Affairs and Operations
|